Global clinical stage pharma firm Contineum Therapeutics’ experimental multiple sclerosis drug has failed to show meaningful benefit in a mid-stage clinical study, the company has reported.

Topline results from the Phase 2 VISTA trial show that PIPE-307 — an M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS) — did not meet its primary or secondary efficacy endpoints. Patients on the drug saw no significant improvement in binocular 2.5% low-contrast letter acuity, a key vision-based measure often used in MS trials.

Safety and tolerability at both tested doses were deemed acceptable, and the company says it is still analyzing exploratory endpoints for any additional signals.

“We’re disappointed by these results, but are grateful to the VISTA trial investigators, and especially to the patients and their families,” said Timothy Watkins, Contineum’s Chief Medical Officer and Head of Development.

“We intend to learn from these data and remain committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases," he added.

The VISTA study was a randomized, double-blind, placebo-controlled, multi-center proof-of-concept trial evaluating both clinical and imaging markers of disease activity in RRMS.

Contineum plans to present the full dataset at an upcoming medical meeting and publish detailed results in a peer-reviewed journal.